Answers are grounded in this paper and cite their sources.
Case report reveals mechanisms of cisplatin-induced myelosuppression in pediatric osteosarcoma, implying critical pharmacogenomic considerations.
A 10-year-old female with osteoblastic osteosarcoma developed life-threatening cisplatin-induced myelosuppression (grade IV neutropenia/thrombocytopenia) following the eighth cycle of MAP chemotherapy. Critical pharmacological findings include a cumulative cisplatin dose of 720 mg/m 2 exceeding the pediatric safety threshold of 400 mg/m 2 . The CYP3A5*1/*1 genotype prolonged the half-life of cisplatin to 8.2 h. Cisplatin-specific biomarkers included serum magnesium 1.2 mg/dL and urinary N-acetyl-β-D-glucosaminidase 48 U/L. Targeted interventions (G-CSF, romiplostim, meropenem) led to hematological recovery within 14 days. This case implicates cisplatin overdose with impaired metabolic clearance as the primary toxicity mechanism.
No takes yet. Share an insight, caveat, or question.
Dai et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: